Having trouble accessing articles? Reset your cache.

Apremilast: Phase III data

Top-line data from the double-blind, international Phase III PALACE-4 trial in 529 active psoriatic arthritis patients who had not previously received a DMARD showed that twice-daily 20 and 30 mg oral apremilast each met the

Read the full 355 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE